The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001373369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
9/10/2026
Date registered
Help: Date registered
16/11/2026
Date last updated
Help: Date last updated
16/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluation of subcutaneous injections of benzathine penicillin G for prevention of recurrent cellulitis
Scientific title
Evaluation of subcutaneous injections of benzathine penicillin G for prevention of recurrent cellulitis
Additional trial identifiers [1] 318621 0
Nil
Universal Trial Number (UTN)
Trial acronym
SCIP Cellulitis
Related trial records

Health condition
Health condition(s) studied:
Cellulitis 343826 0
Recurrent cellulitis 343827 0
Condition category
Condition code
Infection 339968 339968 0 0
Other infectious diseases
Skin 340162 340162 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Patients with current or recent lower leg cellulitis will be invited to participate and will receiving a dose of subcutaneous 10.8 million units of benzathine penicillin G (termed 'SCIP').

The drug administered is BPG: Bicillin® L-A (Pfizer).
Each vial contains 1.2MU BPG.
Participants will receive 10.8MU equal to 9 vials (20.7mL).
Frequency: Once every 10 weeks (dependent on ongoing participation as below)
Administered in clinic by medical staff (nurse or medical practitioner)

Participants will be invited to return to clinic at the 10 week mark, at which stage they will be offered to participate in either i) ongoing 10 weekly administration of subcutaneous benzathine penicillin G at the same dosing and frequency as above, ii) transitioning to oral prophylaxis with 250mg tablet once daily phenoxymethylpenicillin (standard care for recurrent cellulitis) to complete the 52 week trial period or iii) nil further treatment intervention. This choice will be actively offered only at the 10 week review following initial SCIP. Follow-up in all the above arms will occur out to 52 weeks from enrolment.
Intervention code [1] 335527 0
Prevention
Intervention code [2] 335528 0
Treatment: Drugs
Description of the comparator or control
Nil treatment following the initial 10-week intervention.
Control group
Active

Outcomes
Primary outcome [1] 347136 0
The frequency of adverse events that are causally related to SCIP administration
Timepoint [1] 347136 0
Baseline and daily until the end of the study period (52 weeks post initial dose)
Secondary outcome [1] 469089 0
The self-reported tolerability of SCIP administration
Timepoint [1] 469089 0
On the day of first SCIP infusion, 2, 6 weeks and 52 weeks post-first SCIP infusion
Secondary outcome [2] 469090 0
Time plasma penicillin concentrations remain greater than 10ng/mL between SCIP doses
Timepoint [2] 469090 0
Dried blood spots collected following first SCIP administration, daily following first SCIP dose until discharge, immediately prior to next SCIP dose (if electing further SCIP doses), 2 weeks following 2nd dose (and further)
Secondary outcome [3] 469092 0
Proportion of subjects presenting to hospital with an acute episode of cellulitis
Timepoint [3] 469092 0
Routinely every 4 weeks during study period out to 52 weeks
Secondary outcome [4] 469093 0
Participant pain score of subcutaneous injections
Timepoint [4] 469093 0
On the day of first SCIP infusion, 2, 6 weeks and 52 weeks post-first SCIP infusion
Secondary outcome [5] 469102 0
Tolerability measured as oedema
Timepoint [5] 469102 0
On the day of first SCIP infusion, 2, 6 weeks and 52 weeks post-first SCIP infusion
Secondary outcome [6] 469103 0
Tolerability measured as erythema
Timepoint [6] 469103 0
On the day of first SCIP infusion, 2, 6 weeks and 52 weeks post-first SCIP infusion

Eligibility
Key inclusion criteria
Adults with a current or recent (in preceding 3 years) diagnosis of cellulitis.
Admitted as an inpatient or attending as an outpatient at Fiona Stanley Hospital
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
- Have a history of adverse drug reaction, hypersensitivity or allergy to penicillin;
- Documented cognitive impairment or history of dementia leading to incapacity;
- Have scarring or dermatological conditions affecting skin integrity at the intended site of SCIP administration;
- Planned to receive greater than two (2) weeks of antimicrobials with a beta-lactam as a backbone; or
- Inappropriate to be involved with the study as deemed by the treating team.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 30427 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 46846 0
6150 - Murdoch

Funding & Sponsors
Funding source category [1] 323195 0
Government body
Name [1] 323195 0
South Metropolitan Health Service
Country [1] 323195 0
Australia
Funding source category [2] 323197 0
University
Name [2] 323197 0
Curtin University
Country [2] 323197 0
Australia
Primary sponsor type
Individual
Name
A/Prof. Laurens Manning- Fiona Stanley Hospital
Address
Country
Australia
Secondary sponsor category [1] 326165 0
None
Name [1] 326165 0
None
Address [1] 326165 0
Country [1] 326165 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321598 0
WA Health Central HREC
Ethics committee address [1] 321598 0
Ethics committee country [1] 321598 0
Australia
Date submitted for ethics approval [1] 321598 0
10/03/2026
Approval date [1] 321598 0
29/06/2026
Ethics approval number [1] 321598 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 154210 0
A/Prof Laurens Manning
Address 154210 0
Fiona Stanley Hospital, 11 Robbin Warren Drive, Murdoch, Western Australia , 6150
Country 154210 0
Australia
Phone 154210 0
+61 8 6151 1146
Fax 154210 0
Email 154210 0
Contact person for public queries
Name 154211 0
Laurens Manning
Address 154211 0
Fiona Stanley Hospital, 11 Robbin Warren Drive, Murdoch, Western Australia , 6150
Country 154211 0
Australia
Phone 154211 0
+61 8 6151 1146
Fax 154211 0
Email 154211 0
Contact person for scientific queries
Name 154212 0
Laurens Manning
Address 154212 0
Fiona Stanley Hospital, 11 Robbin Warren Drive, Murdoch, Western Australia , 6150
Country 154212 0
Australia
Phone 154212 0
+61 8 6151 1146
Fax 154212 0
Email 154212 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.